<DOC>
	<DOCNO>NCT02557217</DOCNO>
	<brief_summary>NP202 experimental drug develop Armaron Bio Pty Ltd potential use treatment people heart attack ( MI ) .</brief_summary>
	<brief_title>NP202 Treatment Post -STEMI Left Ventricular Systolic Dysfunction</brief_title>
	<detailed_description>After someone MI , heart 'remodels ' , mean change size shape . This damage lead weaker less efficient , ultimately major heart problem . There drug currently available help prevent remodelling use treatment post-MI . However , still high rate remodelling major heart problem people post-MI . NP202 work different way drug currently approve , show animal study prevent post-MI remodelling . This study ass NP202 versus placebo remodelling 3 month treatment period , 1 month follow</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Dysfunction , Left</mesh_term>
	<criteria>Have confirm ST elevation myocardial infarction ( STEMI ) previous 5 day , meet follow criterion ; ≥ 0.2mV ST elevation 2 V1 V6 lead presentation maximum 12 hour onset symptom Troponin level &gt; 10 x upper limit normal ( ULN ) site 's local laboratory . Successful revascularisation Percutaneous Coronary Intervention ( PCI ) Have leave ventricular dysfunction post STEMI evidence leave ventricular ejection fraction ( LVEF ) ≤40 % confirm echocardiogram screening . Are receive guidelinedirected medical therapy acute MI postMI leave ventricular ( LV ) dysfunction accord national cardiology society/heart association STEMI guideline . Known cardiomyopathy heart failure prior MI . Cardiogenic shock and/or systolic blood pressure &lt; 85mmHg Screening . Clinical history ejection fraction ≤40 % prior MI , multiple prior MIs . Daily use nonsteroidal antiinflammatory drug ( NSAIDs ) and/or cyclooxygenase2 ( COX2 ) inhibitor past month . Presence device/hardware incompatible MRI Estimated glomerular filtration rate ( eGFR ) &lt; 30ml/min Liver function test 3 x ULN due noncardiac disease Have receive investigational research agent within 30 day 5 halflives ( whichever longer ) prior first dose investigational product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>